Loading stock data…
MYGN
$4.21-0.08 (-1.86%)
Market ClosedLast close May 11
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Myriad Genetics, Inc. in the Healthcare sector is trading at $4.21. The stock is currently near its 52-week low of $3.75, remaining 30.3% below its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why MYGN maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.21
Potential Upside
5%
Whystock Fair Value$4.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Hold
Mean target$6.28+49.1%
Range$4.00 – $10.00
Fundamentals
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$479.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-107.39%
Volume
Today's trading volume
1.16M
Recent News
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock
We just covered 10 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026 and Myriad Genetics, Inc. (NASDAQ:MYGN) ranks 8th on this list. Myriad Genetics, Inc. (NASDAQ:MYGN) has been a staple in the 13F portfolio of Glenview Capital since the third quarter of 2019. Back then, this position comprised 3.6 million shares. […]
Myriad Genetics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Myriad Genetics, Inc.'s Q1 2026 earnings call
Myriad Genetics Q1 Earnings Call Highlights
Myriad Genetics (NASDAQ:MYGN) reported first-quarter fiscal 2026 revenue of $200.4 million, reflecting 2% year-over-year growth and landing within the company’s prior guidance range. Management highlighted continued momentum in hereditary cancer testing and GeneSight, partially offset by a year-over
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $870 million at the midpoint. Its non-GAAP loss of $0.09 per share was 34.7% below analysts’ consensus estimates.